Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends.

@article{Gullapalli2010ReninangiotensinaldosteroneSB,
  title={Renin-angiotensin-aldosterone system blockade in high-risk hypertensive patients: current approaches and future trends.},
  author={Nageshwara Gullapalli and Micheal J Bloch and Jan N. Basile},
  journal={Therapeutic advances in cardiovascular disease},
  year={2010},
  volume={4 6},
  pages={359-73}
}
Agents that block the renin-angiotensin-aldosterone system (RAAS) are the cornerstones of antihypertensive therapy in patients at high risk for cardiovascular or renal disease. Recently, it was shown that activation of RAAS may occur through alternate pathways not inhibited by angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), or mineralocorticoid receptor antagonists (MRAs), and that ACEIs, ARBs, or MRAs may actually cause a reactive increase in plasma… CONTINUE READING